<?xml version="1.0" encoding="utf-8"?>
<journal>
<title>Caspian Journal of Internal Medicine</title>
<title_fa></title_fa>
<short_title>Caspian J Intern Med</short_title>
<subject>Medical Sciences</subject>
<web_url>http://caspjim.com</web_url>
<journal_hbi_system_id>1</journal_hbi_system_id>
<journal_hbi_system_user>admin</journal_hbi_system_user>
<journal_id_issn>2008-6164</journal_id_issn>
<journal_id_issn_online>2008-6172</journal_id_issn_online>
<journal_id_pii>8</journal_id_pii>
<journal_id_doi>10.22088/cjim</journal_id_doi>
<journal_id_iranmedex></journal_id_iranmedex>
<journal_id_magiran></journal_id_magiran>
<journal_id_sid>14</journal_id_sid>
<journal_id_nlai>8888</journal_id_nlai>
<journal_id_science>13</journal_id_science>
<language>en</language>
<pubdate>
	<type>jalali</type>
	<year>1395</year>
	<month>1</month>
	<day>1</day>
</pubdate>
<pubdate>
	<type>gregorian</type>
	<year>2016</year>
	<month>4</month>
	<day>1</day>
</pubdate>
<volume>7</volume>
<number>2</number>
<publish_type>online</publish_type>
<publish_edition>1</publish_edition>
<article_type>fulltext</article_type>
<articleset>
	<article>


	<language>en</language>
	<article_id_doi></article_id_doi>
	<title_fa></title_fa>
	<title>Influence of methadone on clopidogrel in addicts on methadone maintenance therapy</title>
	<subject_fa>pharmacology</subject_fa>
	<subject>pharmacology</subject>
	<content_type_fa>Original Article</content_type_fa>
	<content_type>Original Article</content_type>
	<abstract_fa></abstract_fa>
	<abstract>&lt;p dir=&quot;ltr&quot; style=&quot;text-align: justify;&quot;&gt;&lt;span style=&quot;font-family: times new roman;&quot;&gt;&lt;span style=&quot;color: rgb(0, 0, 255);&quot;&gt;&lt;strong&gt;&lt;em&gt;Background: &lt;/em&gt;&lt;/strong&gt;&lt;/span&gt;Clopidogrel is a prodrug that converts in the liver to an active thiol metabolite, which irreversibly inhibits the platelet P2Y&lt;sub&gt;12&lt;/sub&gt; adenosine diphosphate receptor. It seems that methadone as CYP2C19 inhibitor affects ticlopidine activity i&lt;em&gt;n vivo&lt;/em&gt;. This study aimed to test the ability of methadone in changing ticlopidine pharmacokinetics.&lt;/span&gt;&lt;/p&gt;

&lt;p dir=&quot;ltr&quot; style=&quot;text-align: justify;&quot;&gt;&lt;span style=&quot;font-family: times new roman;&quot;&gt;&lt;span style=&quot;color: rgb(0, 0, 255);&quot;&gt;&lt;strong&gt;&lt;em&gt;Methods:&lt;/em&gt;&lt;/strong&gt;&lt;/span&gt; We conducted a case&amp;ndash;control study in 10 subjects. The cases (5 subjects) in our study were addicts who were receiving methadone maintenance treatment (MMT) for preventing opium withdrawal symptoms.&amp;nbsp; The control group were opiate users before starting MMT. In both groups, the patients received clopidogrel (75mg/day) for 5 days. On the 6&lt;sup&gt;th&lt;/sup&gt; day, the subjects returned to the clinic, blood samples were taken up to 12 hours following clopidogrel dosing in case and&amp;nbsp; control groups. Plasma concentration of clopidogrel was measured by GC-MAS. Noncompartmental pharmacokinetic analysis was performed using Microsoft Excel software to estimate PK parameters.&lt;/span&gt;&lt;/p&gt;

&lt;p dir=&quot;ltr&quot; style=&quot;text-align: justify;&quot;&gt;&lt;span style=&quot;font-family: times new roman;&quot;&gt;&lt;span style=&quot;color: rgb(0, 0, 255);&quot;&gt;&lt;strong&gt;&lt;em&gt;Results:&lt;/em&gt;&lt;/strong&gt;&lt;/span&gt; In this study, methadone decreased clopidogrel clearance by 25% and increased the AUC&lt;sub&gt;0-inf&lt;/sub&gt; nearly 1.3 fold during the coadministration of clopidogrel as an antiplatelet drug.&lt;/span&gt;&lt;/p&gt;

&lt;p dir=&quot;ltr&quot; style=&quot;text-align: justify;&quot;&gt;&lt;span style=&quot;font-family: times new roman;&quot;&gt;&lt;span style=&quot;color: rgb(0, 0, 255);&quot;&gt;&lt;strong&gt;&lt;em&gt;Conclusion:&lt;/em&gt;&lt;/strong&gt;&lt;/span&gt; A significant decrease in the clearance of clopidogrel during the coadministration of methadone consistent with a decrease in clopidogrel conversion to its active metabolite and this may decrease its efficacy and may have life-threatening consequences for the patients undergoing clopidogerel maintenance therapy&lt;/span&gt;&lt;/p&gt;
</abstract>
	<keyword_fa></keyword_fa>
	<keyword>Clopidogrel, Methadone, Interaction </keyword>
	<start_page>133</start_page>
	<end_page>135</end_page>
	<web_url>http://caspjim.com/browse.php?a_code=A-10-256-1&amp;slc_lang=en&amp;sid=1</web_url>


<author_list>
	<author>
	<first_name>Ferigol</first_name>
	<middle_name></middle_name>
	<last_name>Fallah</last_name>
	<suffix></suffix>
	<first_name_fa></first_name_fa>
	<middle_name_fa></middle_name_fa>
	<last_name_fa></last_name_fa>
	<suffix_fa></suffix_fa>
	<email></email>
	<code>10031947532846005290</code>
	<orcid>10031947532846005290</orcid>
	<coreauthor>No</coreauthor>
	<affiliation>Psychiatry and Behavioral Sciences Research Center, Mazandaran University of Medical Sciences, Sari, Iran</affiliation>
	<affiliation_fa></affiliation_fa>
	 </author>


	<author>
	<first_name>Abolhasan</first_name>
	<middle_name></middle_name>
	<last_name>Hamidikenari</last_name>
	<suffix></suffix>
	<first_name_fa></first_name_fa>
	<middle_name_fa></middle_name_fa>
	<last_name_fa></last_name_fa>
	<suffix_fa></suffix_fa>
	<email></email>
	<code>10031947532846005291</code>
	<orcid>10031947532846005291</orcid>
	<coreauthor>No</coreauthor>
	<affiliation>Psychiatry and Behavioral Sciences Research Center, Mazandaran University of Medical Sciences, Sari, Iran</affiliation>
	<affiliation_fa></affiliation_fa>
	 </author>


	<author>
	<first_name>Seyed Navid</first_name>
	<middle_name></middle_name>
	<last_name>Sajadi</last_name>
	<suffix></suffix>
	<first_name_fa></first_name_fa>
	<middle_name_fa></middle_name_fa>
	<last_name_fa></last_name_fa>
	<suffix_fa></suffix_fa>
	<email></email>
	<code>10031947532846005292</code>
	<orcid>10031947532846005292</orcid>
	<coreauthor>No</coreauthor>
	<affiliation>Molecular and Cell Biology Research Center, Mazandaran University of Medical Sciences, Sari, Iran</affiliation>
	<affiliation_fa></affiliation_fa>
	 </author>


	<author>
	<first_name>Seyed Rohollah </first_name>
	<middle_name></middle_name>
	<last_name>Sajadi</last_name>
	<suffix></suffix>
	<first_name_fa></first_name_fa>
	<middle_name_fa></middle_name_fa>
	<last_name_fa></last_name_fa>
	<suffix_fa></suffix_fa>
	<email></email>
	<code>10031947532846005293</code>
	<orcid>10031947532846005293</orcid>
	<coreauthor>No</coreauthor>
	<affiliation>. Molecular and Cell Biology Research Center, Mazandaran University of Medical Sciences, Sari, Iran.</affiliation>
	<affiliation_fa></affiliation_fa>
	 </author>


	<author>
	<first_name>Mohammad Reza</first_name>
	<middle_name></middle_name>
	<last_name>Shiran</last_name>
	<suffix></suffix>
	<first_name_fa></first_name_fa>
	<middle_name_fa></middle_name_fa>
	<last_name_fa></last_name_fa>
	<suffix_fa></suffix_fa>
	<email>mr.shiran@gmail.com</email>
	<code>10031947532846005294</code>
	<orcid>10031947532846005294</orcid>
	<coreauthor>Yes
</coreauthor>
	<affiliation>Immunogenetics Research Center, Faculty of Medicine, Mazandaran University of Medical Sciences, Sari, Iran</affiliation>
	<affiliation_fa></affiliation_fa>
	 </author>


</author_list>


	</article>
</articleset>
</journal>
